Melissa Bednarek, PT, DPT, PhD, CCSChatham University

Pittsburgh, PA

PHARMACOLOGYPharmacological Management for Cardiovascular Conditions

Independent Study Course 28.4.1

CONTINUING PHYSICAL THERAPY EDUCATION

14

1. Maher ML, Hanlon JT, Hajjar ER. Clinical consequences of polypharmacy in the elderly. Expert Opin Drug Saf. 2014;13(1):57-65. doi: 10.1517/14740338.2013.827660. Epub 2013 Sep 27.

2. Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging. 2013;30(5):285-307.

3. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simp-son KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383-389.

4. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901-910. doi: 10.1002/pds.1984.

5. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polyphar-macy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6):666-671.

6. Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reac-tions in older veterans. J Am Geriatric Soc. 2012;60(1):34-41. doi: 10.1111/j.1532-5415.2011.03772.x. Epub 2011 Dec 8.

7. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116.

8. Crentsil V, Ricks MO, Xue QL, Fried LP. A pharmacoep-idemiologic study of community dwelling, disabled older women: factors associated with medication use. Am J Geriatr Pharmacother. 2010;8(3):215-224. doi: 10.1016/j.amjopharm.2010.06.003.

9. Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20(5):514-522. doi: 10.1002/pds.2116. Epub 2011 Feb 9.

10. Tromp AM, Plujim SM, Smit JH, Deeg DJ, Bouter LM, Lips P. Fall-risk screening test: a positive study of predictors for falls in community-dwelling elderly. J Clin Epidemiol. 2001;54(8):837-844.

11. Nuotio M, Jylhä M, Luukkaala T, Tammela TL. Health problems associated with lower urinary tract symptoms in older women. A population-based survey. Scand J Prim Health Care. 2005;23(4):209-214.

12. Riker GI, Setter SM. Polypharmacy in older adults at home, what it is and what to do about it- implications

for home healthcare and hospice. Home Health Nurse. 2012;30(8):474-485.

13. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10): e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25.

14. Dunlay SM, Weston SA, Jacobsen SJ, Roger VL. Risk factors for heart failure: a population-based case-con-trol study. Am J Med. 2009;122(11):1023-1028. doi: 10.1016/j.amjmed.2009.04.022.

15. American Heart Association. Types of Heart Failure. www.heart.org/HEARTORG/Conditions/HeartFailure/About-HeartFailure/Types-of-Heart-Failure_UCM_306323_Ar-ticle.jsp#.WKo9wIWcHIU. Accessed February 19, 2017.

16. UpToDate. Colucci WS. Overview of the therapy of heart failure with reduced ejection fraction. In: UpToDate. Gottlieb SS,ed. https://www.uptodate.com/. Accessed February 19, 2017.

17. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810-1852. doi: 10.1161/CIR.0b013e31829e8807. Epub 2013 Jun 5.

18. Silverthorn DU. Human physiology: an Integrated Ap-proach. 5th ed. San Francisco, CA: Benjamin Cummings; 2009.

19. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diag-nosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-1847. doi: 10.1093/eurheartj/ehs104. Epub 2012 May 19.

20. UpToDate. Colucci WS. Pharmacologic therapy of heart failure with reduced ejection fraction. In: UpToDate. Gottlieb SS, ed. https://www.uptodate.com/. Accessed February 19, 2017.

21. Gladson B. Pharmacology for Rehabilitation Professionals. 2nd ed. St. Louis, MO: Elsevier Saunders; 2011.

22. The CONSENSUS Trial Study Group. Effects of enal-april on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enal-april Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-1435.

23. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin re-ceptor blockers in heart failure: meta-analysis of random-

REFERENCES

15

ized controlled trials. J Am Coll Cardiol. 2002;39(3): 463-470.

24. CIBIS-II Investigators: The Cardiac Insufficiency Bisop-rolol Study II (CIBIS-II): A randomised trial. Lancet. 1999;353(9146):9-13.

25. Ritchie C. Rating of perceived exertion (RPE). J Physioth-er. 2012;58(1):62. doi: 10.1016/S1836-9553(12)70078-4.

26. Weber KT, Brilla CG, Campbell SE, Zhou G, Matsub-ara L, Guarda E. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press. 1992;1(2):75-85.

27. Weber KT, Villarreal D. Aldosterone and antialdoste-rone therapy in congestive heart failure. Am J Cardiol. 1993;71(3):3A-11A.

28. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotension II suppression. J Endocrinol. 1981;91(3):457-465.

29. The RALES Investigators. Effectiveness of spironolactone added to an angiotension-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78(8):902-907.

30. Lonn E, McKelvie R. Drug treatment in heart failure. BMJ. 2000;320(7243):1188-1192.

31. Rx List. Lanoxin Tablets. www.rxlist.com/lanoxin-tab-lets-drug/clinical-pharmacology.htm. Accessed March 28, 2017.

32. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac co-morbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281-2293. doi: 10.1016/j.jacc.2014.08.036. Epub 2014 Nov 24.

33. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392. doi: 10.1056/NEJ-Moa1313731.

34. Pandey A, Parashar A, Kumbhani DJ, et al. Exercise training in patients with heart failure and preserved ejec-tion fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8(1):33-40. doi: 10.1161/CIR-CHEARTFAILURE.114.001615. Epub 2014 Nov 16.

35. American Heart Association. Angina in women can be different than men. www.heart.org/HEARTORG/Condi-tions/HeartAttack/WarningSignsofaHeartAttack/Angina-in-Women-Can-Be-Different-Than-Men_UCM_448902_Article.jsp#.WN3MCIWcHIU. Accessed March 30, 2017.

36. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J Med. 1996;334(20):1311-1315.

37. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis

and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physi-cians, American Association for Thoracic Surgery, Preven-tive Cardiovascular Nurses Association, Society for Car-diovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354-e471. doi: 10.1161/CIR.0b013e318277d6a0. Epub 2012 Nov 19.

38. Braunwald E. Mechanism of action of calcium-channel- blocking agents. N Engl J Med. 1982;307(26):1618-1627.

39. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus mono-therapy in patients with stable angina pectoris results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1996;27(2):311-316.

40. UpToDate. Kannam JP, Gersh BJ. Nitrates in the man-agement of stable angina pectoris. https://www.uptodate.com/. Accessed April 22, 2017.

41. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-eleva-tion myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the man-agement of patients with acute myocardial infarction). Circulation. 2004;110(5):588-636.

42. UpToDate. Reeder GS, Kennedy HL. Overview of the non-acute management of ST elevation myocardial infarc-tion. https://www.uptodate.com/. Accessed February 21, 2017.

43. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.

44. UpToDate. Spencer FA, Guyatt G, Hennekens CH. Aspi-rin in the primary prevention of cardiovascular disease and cancer. https://www.uptodate.com/. Accessed September 17, 2017.

45. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-ele-vation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Cir-culation. 2013;127(4):e362-e425. doi: 10.1161/CIR.0b013e3182742cf6. Epub 2012 Dec 17.

46. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718.

16

47. UpToDate. Makielski JC. Myocardial Action potential and action of antiarrhthymic drugs. https://www.upto-date.com/. Accessed February 23, 2017.

48. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial. N Engl J Med. 1991;324(12):781-788.

49. Haugh KH. Antidysrhythmic agents at the turn of the twenty-first century: a current review (abstract). Crit Care Nurs Clin North Am. 2002;14(1):53-69.

50. Crim MT, Yoon SS, Ortiz E, et al. National surveillance definitions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes. 2012;5(3):343–351. doi: 10.1161/circoutcomes.111.963439. Epub 2012 May 1.

51. Abbasi J. Medical students fall short on blood pres-sure check challenge. JAMA. 2017;318(11):991-992. doi:10.1001/jama.2017.11255.

52. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experi-mental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcom-mittee of Professional and Public Education of the Amer-ican Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697-716.

53. UpToDate. Basile J, Bloch MJ. Overview of hypertension in adults. https://www.uptodate.com/. Accessed February 23, 2017.

54. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. doi: 10.1001/jama.2013.284427.

55. UpToDate. Mann JFE. Choice of drug therapy in primary (essential) hypertension. https://www.uptodate.com/. Accessed February 23, 2017.

56. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172(22):1739-1744. doi: 10.1001/2013.jamaint-ernmed.469.

57. Antithrombotic Trialists’s Collaboration. Collaboration meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.

58. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxy-genase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817.

59. MacDonald T, Wei L. Effect of ibuprofen on cardiopro-tective effect of aspirin. Lancet. 2003;361(9357):573-574.